# AMX0035 and Progressive Supranuclear Palsy

> **NCT06122662** · PHASE2,PHASE3 · COMPLETED · sponsor: **Amylyx Pharmaceuticals Inc.** · enrollment: 139 (actual)

## Conditions studied

- Progressive Supranuclear Palsy
- PSP
- Neurodegenerative Diseases
- Atypical Parkinsonism

## Interventions

- **DRUG:** AMX0035
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06122662
- **Lead sponsor:** Amylyx Pharmaceuticals Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-12-21
- **Primary completion:** 2025-09-30
- **Final completion:** 2025-10-21
- **Target enrollment:** 139 (ACTUAL)
- **Last updated:** 2026-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06122662

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06122662, "AMX0035 and Progressive Supranuclear Palsy". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06122662. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*